Skip to content

RAPid SimPLE Targeted Radiation Treatment for Brain Metastases

Brain Metastases, Adult

The aim of the study is to show that rapid, simple targeted radiotherapy to brain metastases with 8 Gy / 1 is non-inferior to 20 Gy / 5 in terms of overall survival for patients with poor prognosis.

null

Conditions de participation

  • Sexe:

    ALL
  • Âges admissibles:

    18 and up

Critères de participation

Inclusion Criteria:

Subjects must meet all of the following criteria to be eligible for participation in this study:

* Age ≥ 18
* Pathological diagnosis of a non-hematopoietic malignancy
* Brain metastases of any size
* Any number of brain metastases that can all be contoured and targeted
* Anticipated median survival insufficient for surgery or stereotactic radiosurgery
* Presence of extracranial disease
* Estimated Glomerular Filtration Rate (eGFR) \> 30 ml/min within 90 days
* Diagnosis-Specific Graded Prognostic Assessment (DS-GPA) ≤ 2.0
* Able to complete the EuroQOL (EQ-5D-5L) questionnaire
* Willing and able to have regular imaging follow up
* Feasible to start protocol treatment within 14 days of patient enrolment
* Karnofsky Performance Score (KPS) ≥ 40
* Willing to provide email address on the informed consent form, if unable to attend in-person follow-up assessments
* Signed a consent form prior to enrolment in the trial

Exclusion Criteria:

Subjects are excluded from the study if any of the following criteria apply:

* Inability to have a brain MRI.
* Craniotomy less than 3 months prior to randomization
* Whole brain radiotherapy less than 6 months prior to randomization
* Immunotherapy, targeted therapy or hormone therapy planned after RT
* Disseminated leptomeningeal disease
* Multiple sclerosis
* Neurologically declining despite corticosteroids
* Requiring craniotomy to relieve mass effect
* Systemic lupus erythematosis, scleroderma, or other connective tissue disorders not in remission
* Active alcohol or drug abuse
* History of epilepsy or seizures, and not currently taking anti-epileptic medication
* Any other serious intercurrent illness or medical condition judged by the local investigator to compromise the patient's safety, preclude safe administration of the planned protocol treatment, or prevent the patient from being managed according to the protocol guidelines
* Pregnancy
* Potentially fertile men or women of childbearing potential who are unwilling to employ highly effective contraception

Lieu de l'étude

BC Cancer - Prince George
BC Cancer - Prince George
Prince George, British Columbia
Canada

Contactez l'équipe d'étude

Primary Contact

Robert Olson, MD MSc FRCPC

[email protected]
25064573000
BC Cancer - Kelowna
BC Cancer - Kelowna
Kelowna, British Columbia
Canada

Contactez l'équipe d'étude

Primary Contact

Benjamin Mou, MD FRCPC DABR

[email protected]
250-712-3900
BC Cancer - Victoria
BC Cancer - Victoria
Victoria, British Columbia
Canada

Contactez l'équipe d'étude

Primary Contact

Isabelle Vallieres, MD MSc FRCPC

[email protected]
2505195577
BC Cancer - Surrey
BC Cancer - Surrey
Surrey, British Columbia
Canada

Contactez l'équipe d'étude

Primary Contact

Sarah Baker, MD

604.930.2098
BC Cancer - Vancouver
BC Cancer - Vancouver
Vancouver, British Columbia
Canada

Contactez l'équipe d'étude

Primary Contact

Alan Nichol, MD

[email protected]
604-877-6046
BC Cancer - Abbotsford
BC Cancer - Abbotsford
Abbotsford, British Columbia
Canada

Contactez l'équipe d'étude

Primary Contact

Fred Hsu, BSc MD FRCPC

6048514710
Étude parrainée par
British Columbia Cancer Agency
Participants recherchés
Plus d'informations
ID de l'étude: NCT05050929